| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Investor presentation |
| 06/07/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
8-K
| Other Events Interactive Data |
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/28/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/14/2023 |
SC 13G
| AWM Investment Company, Inc. reports a 10% stake in Applied DNA Sciences, Inc. |
| 02/09/2023 |
SC 13G/A
| Grossman Bruce reports a 4.9% stake in Applied DNA Sciences, Inc. |
| 02/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/09/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/27/2023 |
4
| SHAMASH YACOV A (Director) has filed a Form 4 on APPLIED DNA SCIENCES INC|
Txns:
| Granted 75,099 options to buy
@ $1.41, valued at
$105.9k
Granted 46,938 options to buy
@ $1.41, valued at
$66.2k
|
|
| 01/27/2023 |
4
| Anchin Scott L (Director) has filed a Form 4 on APPLIED DNA SCIENCES INC|
Txns:
| Granted 75,099 options to buy
@ $1.41, valued at
$105.9k
Granted 37,550 options to buy
@ $1.41, valued at
$52.9k
|
|
| 01/27/2023 |
4
| Ceccoli Joseph D. (Director) has filed a Form 4 on APPLIED DNA SCIENCES INC|
Txns:
| Granted 75,099 options to buy
@ $1.41, valued at
$105.9k
Granted 41,305 options to buy
@ $1.41, valued at
$58.2k
|
|
| 01/27/2023 |
4
| Simon Sanford R (Director) has filed a Form 4 on APPLIED DNA SCIENCES INC|
Txns:
| Granted 75,099 options to buy
@ $1.41, valued at
$105.9k
Granted 38,489 options to buy
@ $1.41, valued at
$54.3k
|
|
| 01/27/2023 |
4
| Schmalz Elizabeth M (Director) has filed a Form 4 on APPLIED DNA SCIENCES INC|
Txns:
| Granted 75,099 options to buy
@ $1.41, valued at
$105.9k
Granted 40,366 options to buy
@ $1.41, valued at
$56.9k
|
|
| 01/27/2023 |
4
| CATELL ROBERT B (Director) has filed a Form 4 on APPLIED DNA SCIENCES INC|
Txns:
| Granted 75,099 options to buy
@ $1.41, valued at
$105.9k
Granted 39,428 options to buy
@ $1.41, valued at
$55.6k
|
|
| 01/27/2023 |
10-K/A
| Annual Report for the period ended September 30, 2022 [amend] |
| 12/14/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
10-K
| Annual Report for the period ended September 30, 2022 |
| 09/23/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/11/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/10/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/08/2022 |
8-K
| Quarterly results |
| 08/08/2022 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/05/2022 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/05/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|